Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
paper
Cited
Public
Unavailable
- Authors
- Heilig, Markus; Egli, Mark
- Year
- 2006
- Journal
- Pharmacology & therapeutics
- PMID
- 16545872
- DOI
- 10.1016/j.pharmthera.2006.02.001
Alcoholism is a major public health problem and resembles, in many ways, other chronic relapsing medical conditions. At least 2 separate dimensions of its symptomatology offer targetable pathophysiological mechanisms. Systems that mediate positive reinforcement by alcohol are likely important targets in early stages of the disease, particularly in genetically susceptible individuals. In contrast, long term neuroadaptive changes caused by chronic alcohol use primarily appear to affect systems mediating negative affective states, and gain importance following a prolonged history of dependence. Feasibility of pharmacological treatment in alcoholism has been demonstrated by a first wave of drugs which consists of 3 currently approved medications, the aldehyde dehydrogenase blocker disulfiram, the opioid antagonist naltrexone (NTX) and the functional glutamate antagonist acamprosate (ACM). The treatment toolkit is likely to be expanded in the near future. This will improve overall efficacy and allow individualized treatment, ultimately taking in account the patient's genetic makeup. In a second wave, early human efficacy data are available for the 5HT3 antagonist ondansetron, the GABA-B agonist baclofen and the anticonvulsant topiramate. The third wave is comprised of compounds predicted to be effective based on a battery of animal models. Using such models, a short list of additional targets has accumulated sufficient preclinical validation to merit clinical development. These include the cannabinoid CB1 receptor, receptors modulating glutamatergic transmission (mGluR2, 3 and 5), and receptors for stress-related neuropeptides corticotropin releasing factor (CRF), neuropeptide Y (NPY) and nociceptin. Once novel treatments are developed, the field faces a major challenge to assure their delivery to patients.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Repurposing GLP-1 receptor agonists for alcohol use disorder: a systematic review and meta-analysis. | Nasrollahizadeh A et al. | β | 2026 | β |
| Characterizing midlife-onset alcohol dependence: Implications for etiology, prevention, and healthy aging. | Khalifeh L et al. | β | 2025 | β |
| Ethanol self-administration targets GluA2-containing AMPA receptor expression and synaptic activity in the nucleus accumbens in a manner that drives the positive reinforcing properties of the drug. | Faccidomo S et al. | β | 2025 | β |
| Prenatal substance exposure and infant neurodevelopment: a review of magnetic resonance imaging studies. | Shah L et al. | β | 2025 | β |
| Role of Metabolism onΒ Alcohol Preference, Addiction, and Treatment. | Quintanilla ME et al. | β | 2025 | β |
| Bad habits-good goals? Meta-analysis and translation of the habit construct to alcoholism. | Giannone F et al. | β | 2024 | β |
| Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment options. | Corley C et al. | β | 2024 | β |
| Kappa-opioid receptor antagonism in the nucleus accumbens shell distinguishes escalated alcohol consumption and negative affective-like behavior from physiological withdrawal in alcohol-dependence. | Lepreux G et al. | β | 2024 | β |
| Neuronal nicotinic acetylcholine receptor of the central amygdala modulates the ethanol-induced tolerance to anxiolysis and withdrawal-induced anxiety in male rats. | Duratkar A et al. | β | 2024 | β |
| Operant alcohol self-administration targets GluA2-containing AMPA receptor expression and synaptic activity in the nucleus accumbens in a manner that drives the positive reinforcing properties of the drug | Faccidomo S et al. | β | 2024 | β |
| The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats. | AranΓ€s C et al. | β | 2024 | β |
| Alcohol reverses the effects of KCNJ6 (GIRK2) noncoding variants on excitability of human glutamatergic neurons. | Popova D et al. | β | 2023 | β |
| Alcohol-specific transcriptional dynamics of memory reconsolidation and relapse. | Goltseker K et al. | β | 2023 | β |
| Antismoking agents do not contribute synergistically to semaglutide's ability to reduce alcohol intake in rats. | AranΓ€s C et al. | β | 2023 | β |
| Assessing the Behavioral and Personality Changes in Alcohol Dependence Syndrome in Wardha, Central India. | Ray A et al. | β | 2023 | β |
| Effects of Taurine in Mice and Zebrafish Behavioral Assays With Translational Relevance to Schizophrenia. | Giongo FK et al. | β | 2023 | β |
| Improvement of the Metabolic Stability of GPR88 Agonist RTI-13951-33: Design, Synthesis, and Biological Evaluation. | Rahman MT et al. | β | 2023 | β |
| Negative modulation of AMPA receptors bound to transmembrane AMPA receptor regulatory protein Ξ³-8 blunts the positive reinforcing properties of alcohol and sucrose in a brain region-dependent manner in male mice. | Hoffman JL et al. | β | 2023 | β |
| Novel RXFP3 negative allosteric modulator RLX-33 reduces alcohol self-administration in rats. | Van Voorhies KJ et al. | β | 2023 | β |
| Recapitulating phenotypes of alcohol dependence via overexpression of Oprk1 in the ventral tegmental area of non-dependent TH::Cre rats. | Lepreux G et al. | β | 2023 | β |
| Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. | AranΓ€s C et al. | β | 2023 | β |
| Attenuation of the levels of pro-inflammatory cytokines prevents depressive-like behavior during ethanol withdrawal in mice. | Fraga-Junior EB et al. | β | 2022 | β |
| Function of Retinoic Acid in Development of Male and Female Gametes. | Schleif MC et al. | β | 2022 | β |
| Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin. | Tufvesson-Alm M et al. | β | 2022 | β |
| Modeling Aversion Resistant Alcohol Intake in Indiana Alcohol-Preferring (P) Rats. | Katner SN et al. | β | 2022 | β |
| RTICBM-74 Is a Brain-Penetrant Cannabinoid Receptor Subtype 1 Allosteric Modulator that Reduces Alcohol Intake in Rats. | Lovelock DF et al. | β | 2022 | β |
| Assessing effects of oxytocin on alcohol consumption in socially housed prairie voles using radio frequency tracking. | Walcott AT et al. | β | 2021 | β |
| Chemogenetic manipulation of astrocytic signaling in the basolateral amygdala reduces binge-like alcohol consumption in male mice. | Nwachukwu KN et al. | β | 2021 | β |
| Genetically selected alcohol-preferring msP rats to study alcohol use disorder: Anything lost in translation? | Borruto AM et al. | β | 2021 | β |
| Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. | Biernacka JM et al. | β | 2021 | β |
| Inhibition of AMPA receptors (AMPARs) containing transmembrane AMPAR regulatory protein Ξ³-8 with JNJ-55511118 shows preclinical efficacy in reducing chronic repetitive alcohol self-administration. | Hoffman JL et al. | β | 2021 | β |
| Kappa opioid receptor and dynorphin signaling in the central amygdala regulates alcohol intake. | Bloodgood DW et al. | β | 2021 | β |
| Neurobiology of alcohol seeking behavior. | Domi E et al. | β | 2021 | β |
| Outcomes of deep brain stimulation surgery for substance use disorder: a systematic review. | Hassan O et al. | β | 2021 | β |
| Psychometric properties and longitudinal measurement invariance of the drug craving scale: Modification of the Polish version of the Penn Alcohol Craving Scale (PACS). | Opozda-Suder S et al. | β | 2021 | β |
| Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder. | Augier E | β | 2021 | β |
| Targeting the Opioid Receptors: A Promising Therapeutic Avenue for Treatment in "Heavy Drinking Smokers". | Domi A et al. | β | 2021 | β |
| The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. | Agabio R et al. | β | 2021 | β |
| The Persistent Challenge of Developing Addiction Pharmacotherapies. | Swinford-Jackson SE et al. | β | 2021 | β |
| Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. | Jerlhag E | β | 2020 | β |
| Brain Site-Specific Inhibitory Effects of the GLP-1 Analogue Exendin-4 on Alcohol Intake and Operant Responding for Palatable Food. | Colvin KJ et al. | β | 2020 | β |
| Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala. | SuΓ‘rez J et al. | β | 2020 | β |
| Early postnatal allopregnanolone levels alteration and adult behavioral disruption in rats: Implication for drug abuse. | BartolomΓ© I et al. | β | 2020 | β |
| Activation of amylin receptors attenuates alcohol-mediated behaviours in rodents. | Kalafateli AL et al. | β | 2019 | β |
| Association Study of OPRM1 Gene in a Sample of Schizophrenia Patients With Alcohol Dependence or Abuse. | Gendy MNS et al. | β | 2019 | β |
| Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents. | VallΓΆf D et al. | β | 2019 | β |
| Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future. | Cannella N et al. | β | 2019 | β |
| Caenorhabditis elegans as a model system to identify therapeutics for alcohol use disorders. | Katner SN et al. | β | 2019 | β |
| Developing neuroscience-based treatments for alcohol addiction: A matter of choice? | Heilig M et al. | β | 2019 | β |
| Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys. | Flynn SM et al. | β | 2019 | β |
| Mammalian target of rapamycin complex 1 and its downstream effector collapsin response mediator protein-2 drive reinstatement of alcohol reward seeking. | Ben Hamida S et al. | β | 2019 | β |
| MGluR5 activity is required for the induction of ethanol behavioral sensitization and associated changes in ERK MAP kinase phosphorylation in the nucleus accumbens shell and lateral habenula. | Stevenson RA et al. | β | 2019 | β |
| NOP Receptor Antagonists Decrease Alcohol Drinking in the Dark in C57BL/6J Mice. | Brunori G et al. | β | 2019 | β |
| The Human Laboratory and Drug Development in Alcohol Use Disorder: Recent Updates. | Chukwueke CC et al. | β | 2019 | β |
| An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic Ξ±6Ξ²2* antagonist r-bPiDI. | Maggio SE et al. | β | 2018 | β |
| Discovery of a Potent, Selective, and Brain-Penetrant Small Molecule that Activates the Orphan Receptor GPR88 and Reduces Alcohol Intake. | Jin C et al. | β | 2018 | β |
| Dorsal BNST Ξ±<sub>2A</sub>-Adrenergic Receptors Produce HCN-Dependent Excitatory Actions That Initiate Anxiogenic Behaviors. | Harris NA et al. | β | 2018 | β |
| Early post-natal neuroactive steroid manipulation modulates ondansetron effects on initial periods of alcohol consumption in rats. | BartolomΓ© I et al. | β | 2018 | β |
| EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. | European Association for the Study of the Liver | β | 2018 | β |
| GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. | Jerlhag E | β | 2018 | β |
| <i>Caenorhabditis elegans</i> Show Preference for Stimulants and Potential as a Model Organism for Medications Screening. | Engleman EA et al. | β | 2018 | β |
| Medications for alcohol use disorders: An overview. | Akbar M et al. | β | 2018 | β |
| Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction. | Cross AJ et al. | β | 2018 | β |
| Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. | Khoja S et al. | β | 2018 | β |
| The intersection of stress and reward: BNST modulation of aversive and appetitive states. | Ch'ng S et al. | β | 2018 | β |
| A SMART data analysis method for constructing adaptive treatment strategies for substance use disorders. | Nahum-Shani I et al. | β | 2017 | β |
| Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors. | Korpi ER et al. | β | 2017 | β |
| Epigenetics: a link between addiction and social environment. | Ajonijebu DC et al. | β | 2017 | β |
| Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects. | LidΓΆ HH et al. | β | 2017 | β |
| Intermittent Access to Ethanol Induces Escalated Alcohol Consumption in Primates. | Lindell SG et al. | β | 2017 | β |
| Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. | Yardley MM et al. | β | 2017 | β |
| Oxytocin inhibits ethanol consumption and ethanol-induced dopamine release in the nucleus accumbens. | Peters ST et al. | β | 2017 | β |
| Oxytocin reduces alcohol consumption in prairie voles. | Stevenson JR et al. | β | 2017 | β |
| Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder. | Huynh N et al. | β | 2017 | β |
| Rat animal models for screening medications to treat alcohol use disorders. | Bell RL et al. | β | 2017 | β |
| The allostatic impact of chronic ethanol on gene expression: A genetic analysis of chronic intermittent ethanol treatment in the BXD cohort. | van der Vaart AD et al. | β | 2017 | β |
| The GABA<sub>B</sub> Positive Allosteric Modulator ADX71441 Attenuates Alcohol Self-Administration and Relapse to Alcohol Seeking in Rats. | Augier E et al. | β | 2017 | β |
| A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction. | Bell RL et al. | β | 2016 | β |
| Alcohol Interactions with Psychostimulants: An Overview of Animal and Human Studies. | Althobaiti YS et al. | β | 2016 | β |
| Biobehavioral mechanisms of topiramate's effects on alcohol use: an investigation pairing laboratory and ecological momentary assessments. | Miranda R et al. | β | 2016 | β |
| Central histaminergic transmission modulates the ethanol induced anxiolysis in mice. | Verma L et al. | β | 2016 | β |
| Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. | Mann K et al. | β | 2016 | β |
| Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. | Soyka M | β | 2016 | β |
| Single-Dose Interaction Study of the Arginine Vasopressin Type 1B Receptor Antagonist ABT-436 and Alcohol in Moderate Alcohol Drinkers. | Katz DA et al. | β | 2016 | β |
| The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. | Schwandt ML et al. | β | 2016 | β |
| The mGluR2 Positive Allosteric Modulator, AZD8529, and Cue-Induced Relapse to Alcohol Seeking in Rats. | Augier E et al. | β | 2016 | β |
| The Need for Treatment Responsive Translational Biomarkers in Alcoholism Research. | Heilig M et al. | β | 2016 | β |
| The Nociceptin Receptor as an Emerging Molecular Target for Cocaine Addiction. | Lutfy K et al. | β | 2016 | β |
| Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. | Soyka M et al. | β | 2016 | β |
| What the alcohol doctor ordered from the neuroscientist: Theragnostic biomarkers for personalized treatments. | Heilig M et al. | β | 2016 | β |
| Alcohol and violence: neuropeptidergic modulation of monoamine systems. | Miczek KA et al. | β | 2015 | β |
| Anticraving Effect of Baclofen in Alcohol-Dependent Patients. | Imbert B et al. | β | 2015 | β |
| A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. | Bilbao A et al. | β | 2015 | β |
| Ceftriaxone and cefazolin attenuate the cue-primed reinstatement of alcohol-seeking. | Weiland A et al. | β | 2015 | β |
| Chronic alcohol alters rewarded behaviors and striatal plasticity. | DePoy L et al. | β | 2015 | β |
| Cigarettes and alcohol: The influence of nicotine on operant alcohol self-administration and the mesolimbic dopamine system. | Ostroumov A et al. | β | 2015 | β |
| Effects of D-cycloserine on extinction of mesolimbic cue reactivity in alcoholism: a randomized placebo-controlled trial. | Kiefer F et al. | β | 2015 | β |
| Enhancing glutamatergic transmission during adolescence reverses early-life stress-induced deficits in the rewarding effects of cocaine in rats. | O'Connor RM et al. | β | 2015 | β |
| Escalated Aggression in Animal Models: Shedding New Light on Mesocorticolimbic Circuits. | Miczek KA et al. | β | 2015 | β |
| Hominids adapted to metabolize ethanol long before human-directed fermentation. | Carrigan MA et al. | β | 2015 | β |
| Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. | Korpi ER et al. | β | 2015 | β |
| Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for the Treatment of Psychostimulant Dependence. | Li X et al. | β | 2015 | β |
| Preclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation. | Phillips TJ et al. | β | 2015 | β |
| RECK impedes DNA repair by inhibiting the erbB/JAB1/Rad51 signaling axis and enhances chemosensitivity of breast cancer cells. | Hong KJ et al. | β | 2015 | β |
| Structural reorganization of pyramidal neurons in the medial prefrontal cortex of alcohol dependent rats is associated with altered glial plasticity. | Kim A et al. | β | 2015 | β |
| Targeting glutamate uptake to treat alcohol use disorders. | Rao PS et al. | β | 2015 | β |
| The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. | Kwako LE et al. | β | 2015 | β |
| The effects of mirtazapine versus placebo on alcohol consumption in male high consumers of alcohol: a randomized, controlled trial. | de Bejczy A et al. | β | 2015 | β |
| Association of single-nucleotide polymorphisms in a metabotropic glutamate receptor GRM3 gene subunit to alcohol-dependent male subjects. | Xia Y et al. | β | 2014 | β |
| Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons. | Duke AN et al. | β | 2014 | β |
| Brucine suppresses ethanol intake and preference in alcohol-preferring Fawn-Hooded rats. | Li YL et al. | β | 2014 | β |
| Chronic psychosocial stress causes delayed extinction and exacerbates reinstatement of ethanol-induced conditioned place preference in mice. | Bahi A et al. | β | 2014 | β |
| Combined pharmacotherapies for the management of alcoholism: rationale and evidence to date. | Lee MR et al. | β | 2014 | β |
| Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients. | Spagnolo PA et al. | β | 2014 | β |
| Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference. | Pina MM et al. | β | 2014 | β |
| Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism. | Enoch MA | β | 2014 | β |
| Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. | Karpyak VM et al. | β | 2014 | β |
| Genetics and genomics of alcohol sensitivity. | Morozova TV et al. | β | 2014 | β |
| High variability in the exposure of baclofen in alcohol-dependent patients. | Marsot A et al. | β | 2014 | β |
| Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. | Blednov YA et al. | β | 2014 | β |
| Modes of direct modulation by taurine of the glutamate NMDA receptor in rat cortex. | Chan CY et al. | β | 2014 | β |
| [Nalmefene: a novel pharmacotherapeutic option for alcoholism]. | Soyka M | β | 2014 | β |
| Nalmefene for the treatment of alcohol dependence: a current update. | Soyka M | β | 2014 | β |
| Operant self-administration of alcohol and nicotine in a preclinical model of co-abuse. | LΓͺ AD et al. | β | 2014 | β |
| P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders. | Franklin KM et al. | β | 2014 | β |
| Pharmacological approaches to reducing craving in patients with alcohol use disorders. | Haass-Koffler CL et al. | β | 2014 | β |
| Proteomic approaches and identification of novel therapeutic targets for alcoholism. | Gorini G et al. | β | 2014 | β |
| Stress and alcohol interactions: animal studies and clinical significance. | Spanagel R et al. | β | 2014 | β |
| The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. | Moore CF et al. | β | 2014 | β |
| The impact of atrial natriuretic peptide on anxiety, stress and craving in patients with alcohol dependence. | Koopmann A et al. | β | 2014 | β |
| Chromatin remodeling--a novel strategy to control excessive alcohol drinking. | Warnault V et al. | β | 2013 | β |
| Chronic alcohol produces neuroadaptations to prime dorsal striatal learning. | DePoy L et al. | β | 2013 | β |
| Cravings as a mediator and moderator of drinking outcomes in the COMBINE study. | Subbaraman MS et al. | β | 2013 | β |
| Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. | Vasiljevik T et al. | β | 2013 | β |
| Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice. | Peters S et al. | β | 2013 | β |
| Escalation of drug self-administration as a hallmark of persistent addiction liability. | Edwards S et al. | β | 2013 | β |
| Genetically selected alcohol preferring rats to model human alcoholism. | Ciccocioppo R | β | 2013 | β |
| Metabotropic glutamate 7 (mGlu7) receptor: a target for medication development for the treatment of cocaine dependence. | Li X et al. | β | 2013 | β |
| Neuropsychopharmacological actions of taurine. | Banerjee SP et al. | β | 2013 | β |
| Noradrenergic synaptic function in the bed nucleus of the stria terminalis varies in animal models of anxiety and addiction. | McElligott ZA et al. | β | 2013 | β |
| Pharmacological characterization of the 20% alcohol intermittent access model in Sardinian alcohol-preferring rats: a model of binge-like drinking. | Sabino V et al. | β | 2013 | β |
| Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. | Davies DL et al. | β | 2013 | β |
| Role of 5-hydroxytryptamine 1B (5-HT1B) receptors in the regulation of ethanol intake in rodents. | Sari Y | β | 2013 | β |
| Translational approach to develop novel medications on alcohol addiction: focus on neuropeptides. | Ubaldi M et al. | β | 2013 | β |
| A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence. | Wee S et al. | β | 2012 | β |
| Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity. | Bell RL et al. | β | 2012 | β |
| Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment. | Gueorguieva R et al. | β | 2012 | β |
| Conceptualizing withdrawal-induced escalation of alcohol self-administration as a learned, plasticity-dependent process. | Walker BM | β | 2012 | β |
| Dihydromyricetin as a novel anti-alcohol intoxication medication. | Shen Y et al. | β | 2012 | β |
| EASL clinical practical guidelines: management of alcoholic liver disease. | European Association for the Study of Liver | β | 2012 | β |
| Introduction to the special issue "Pharmacotherapies for the treatment of alcohol abuse and dependence" and a summary of patents targeting other neurotransmitter systems. | Bell RL et al. | β | 2012 | β |
| Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates. | Gorsane MA et al. | β | 2012 | β |
| Ivermectin reduces alcohol intake and preference in mice. | Yardley MM et al. | β | 2012 | β |
| Love and addiction: the devil is in the differences: a commentary on "the behavioral, anatomical and pharmacological parallels between social attachment, love and addiction". | Hostetler CM et al. | β | 2012 | β |
| Medications development to treat alcohol dependence: a vision for the next decade. | Litten RZ et al. | β | 2012 | β |
| Opioid system and Alzheimer's disease. | Cai Z et al. | β | 2012 | β |
| Pharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats. | Cippitelli A et al. | β | 2012 | β |
| Rational development of addiction pharmacotherapies: successes, failures, and prospects. | Pierce RC et al. | β | 2012 | β |
| Role for ventral pallidal GABAergic mechanisms in the regulation of ethanol self-administration. | Kemppainen H et al. | β | 2012 | β |
| The clinical significance of drug craving. | Tiffany ST et al. | β | 2012 | β |
| The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. | Srinivasan S et al. | β | 2012 | β |
| The neurobiology of binge-like ethanol drinking: evidence from rodent models. | Sprow GM et al. | β | 2012 | β |
| Urocortins: CRF's siblings and their potential role in anxiety, depression and alcohol drinking behavior. | Ryabinin AE et al. | β | 2012 | β |
| A genetic determinant of the striatal dopamine response to alcohol in men. | Ramchandani VA et al. | β | 2011 | β |
| Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinking. | Tanchuck MA et al. | β | 2011 | β |
| Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study. | Gueorguieva R et al. | β | 2011 | β |
| Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. | Breese GR et al. | β | 2011 | β |
| Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal. | Ripley TL et al. | β | 2011 | β |
| Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats. | Celikyurt IK et al. | β | 2011 | β |
| Enhanced sensitivity to attenuation of conditioned reinstatement by the mGluR 2/3 agonist LY379268 and increased functional activity of mGluR 2/3 in rats with a history of ethanol dependence. | Kufahl PR et al. | β | 2011 | β |
| Ethanol-induced effects on the dopamine and serotonin systems in adult Wistar rats are dependent on early-life experiences. | Oreland S et al. | β | 2011 | β |
| Inhibiting vitamin A metabolism as an approach to male contraception. | Hogarth CA et al. | β | 2011 | β |
| JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. | Galici R et al. | β | 2011 | β |
| Medications for unhealthy alcohol use: across the spectrum. | O'Malley SS et al. | β | 2011 | β |
| Modulation of monoamine receptors by adaptor proteins and lipid rafts: role in some effects of centrally acting drugs and therapeutic agents. | BjΓΆrk K et al. | β | 2011 | β |
| Molecular targets of alcohol action: Translational research for pharmacotherapy development and screening. | Gorini G et al. | β | 2011 | β |
| Pharmacogenetic approaches to the treatment of alcohol addiction. | Heilig M et al. | β | 2011 | β |
| Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. | Umhau JC et al. | β | 2011 | β |
| Plasticity associated with escalated operant ethanol self-administration during acute withdrawal in ethanol-dependent rats requires intact matrix metalloproteinase systems. | Smith AW et al. | β | 2011 | β |
| Role of the serotonergic system in alcohol dependence: from animal models to clinics. | Sari Y et al. | β | 2011 | β |
| Safety and efficacy of long-term disulfiram aftercare. | Mutschler J et al. | β | 2011 | β |
| Stress-induced reinstatement of alcohol-seeking in rats is selectively suppressed by the neurokinin 1 (NK1) antagonist L822429. | Schank JR et al. | β | 2011 | β |
| Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis. | Amory JK et al. | β | 2011 | β |
| Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. | Lyon JE et al. | β | 2011 | β |
| Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. | Paparrigopoulos T et al. | β | 2011 | β |
| ΞΊ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats. | Nealey KA et al. | β | 2011 | β |
| Augmented stress-induced alcohol drinking and withdrawal in mice lacking functional natriuretic peptide-A receptors. | Mutschler J et al. | β | 2010 | β |
| Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. | Olive MF | β | 2010 | β |
| Disulfiram impairs the development of behavioural sensitization to the stimulant effect of ethanol. | Kim AK et al. | β | 2010 | β |
| Effects of the mGlu2/3 agonist LY379268 and the mGlu5 antagonist MTEP on ethanol seeking and reinforcement are differentially altered in rats with a history of ethanol dependence. | Sidhpura N et al. | β | 2010 | β |
| Emerging drugs to treat alcoholism. | Soyka M et al. | β | 2010 | β |
| Genome-wide gene expression analysis identifies K-ras as a regulator of alcohol intake. | Repunte-Canonigo V et al. | β | 2010 | β |
| Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats. | Vengeliene V et al. | β | 2010 | β |
| Long-lasting reduction in hippocampal neurogenesis by alcohol consumption in adolescent nonhuman primates. | Taffe MA et al. | β | 2010 | β |
| MDMA (Ecstasy) decreases the number of neurons and stem cells in embryonic cortical cultures. | Kindlundh-HΓΆgberg AM et al. | β | 2010 | β |
| Metabotropic glutamate receptor 5 activity in the nucleus accumbens is required for the maintenance of ethanol self-administration in a rat genetic model of high alcohol intake. | Besheer J et al. | β | 2010 | β |
| Nalmefene for treatment of alcohol dependence. | Soyka M et al. | β | 2010 | β |
| Neuroplastic alterations in the limbic system following cocaine or alcohol exposure. | Stuber GD et al. | β | 2010 | β |
| New horizons for therapeutics in drug and alcohol abuse. | Jupp B et al. | β | 2010 | β |
| Operant sensation seeking requires metabotropic glutamate receptor 5 (mGluR5). | Olsen CM et al. | β | 2010 | β |
| Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. | George DT et al. | β | 2010 | β |
| Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. | Barr CS et al. | β | 2010 | β |
| Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats. | Cippitelli A et al. | β | 2010 | β |
| The GABAB receptor agonist baclofen administered into the median and dorsal raphe nuclei is rewarding as shown by intracranial self-administration and conditioned place preference in rats. | Shin R et al. | β | 2010 | β |
| The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. | Mason BJ et al. | β | 2010 | β |
| The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol. | Steensland P et al. | β | 2010 | β |
| Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. | Heilig M et al. | β | 2010 | β |
| Using glutamate homeostasis as a target for treating addictive disorders. | Reissner KJ et al. | β | 2010 | β |
| Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. | Czachowski CL et al. | β | 2009 | β |
| Acute interaction of baclofen in combination with alcohol in heavy social drinkers. | Evans SM et al. | β | 2009 | β |
| Alcoholism: a systems approach from molecular physiology to addictive behavior. | Spanagel R | β | 2009 | β |
| Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor. | Carnicella S et al. | β | 2009 | β |
| Cocaine challenge enhances release of neuroprotective amino acid taurine in the striatum of chronic cocaine treated rats: a microdialysis study. | Yablonsky-Alter E et al. | β | 2009 | β |
| Cocaine craving and use during daily life. | Preston KL et al. | β | 2009 | β |
| Complete suppression of craving in alcohol-dependent individuals: is it possible? | Kiefer F | β | 2009 | β |
| Deletion of agouti-related protein blunts ethanol self-administration and binge-like drinking in mice. | Navarro M et al. | β | 2009 | β |
| Effects of topiramate and other anti-glutamatergic drugs on the acute intoxicating actions of ethanol in mice: modulation by genetic strain and stress. | Chen YC et al. | β | 2009 | β |
| Glycine receptor expression in the forebrain of male AA/ANA rats. | Jonsson S et al. | β | 2009 | β |
| Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens. | Besheer J et al. | β | 2009 | β |
| Loop 2 structure in glycine and GABA(A) receptors plays a key role in determining ethanol sensitivity. | Perkins DI et al. | β | 2009 | β |
| Meta-analyses of placebo-controlled trials of acamprosate for the treatment of alcohol dependence: impact of the combined pharmacotherapies and behavior interventions study. | Dranitsaris G et al. | β | 2009 | β |
| Neurobiological mechanisms contributing to alcohol-stress-anxiety interactions. | Silberman Y et al. | β | 2009 | β |
| Permanent impairment of birth and survival of cortical and hippocampal proliferating cells following excessive drinking during alcohol dependence. | Richardson HN et al. | β | 2009 | β |
| Pronounced paranoia as a result of cocaine-disulfiram interaction: case report and mode of action. | Mutschler J et al. | β | 2009 | β |
| Selective reduction of alcohol drinking in Sardinian alcohol-preferring rats by a sigma-1 receptor antagonist. | Sabino V et al. | β | 2009 | β |
| The novel micro-opioid receptor antagonist, [N-allyl-Dmt(1)]endomorphin-2, attenuates the enhancement of GABAergic neurotransmission by ethanol. | Li Q et al. | β | 2009 | β |
| The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. | Addolorato G et al. | β | 2009 | β |
| Trait anxiety and ethanol: anxiolysis in high-anxiety mice and no relation to intake behavior in an addiction model. | Correia D et al. | β | 2009 | β |
| Understanding and treating alcohol craving and dependence: recent pharmacological and neuroendocrinological findings. | Leggio L | β | 2009 | β |
| Withdrawal from free-choice high-fat high-sugar diet induces craving only in obesity-prone animals. | Pickering C et al. | β | 2009 | β |
| Young Investigator Award symposium. | Witkiewitz K et al. | β | 2009 | β |
| Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice. | Gupta T et al. | β | 2008 | β |
| Alcohol dependence, withdrawal, and relapse. | Becker HC | β | 2008 | β |
| Alcohol self-administration acutely stimulates the hypothalamic-pituitary-adrenal axis, but alcohol dependence leads to a dampened neuroendocrine state. | Richardson HN et al. | β | 2008 | β |
| A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration. | Burattini C et al. | β | 2008 | β |
| Analysis of single nucleotide polymorphisms and haplotypes in the neuropeptide Y gene: no evidence for association with alcoholism in a German population sample. | Zill P et al. | β | 2008 | β |
| Association between the nociceptin receptor gene (OPRL1) single nucleotide polymorphisms and alcohol dependence. | Huang J et al. | β | 2008 | β |
| Cellular and behavioral interactions of gabapentin with alcohol dependence. | Roberto M et al. | β | 2008 | β |
| Comparing topiramate with naltrexone in the treatment of alcohol dependence. | Baltieri DA et al. | β | 2008 | β |
| Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes. | Reilly MT et al. | β | 2008 | β |
| Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. | Ji D et al. | β | 2008 | β |
| Effects of olanzapine on ethanol withdrawal syndrome in rats. | Unsalan N et al. | β | 2008 | β |
| In vivo metabotropic glutamate receptor 5 (mGluR5) antagonism prevents cocaine-induced disruption of postsynaptically maintained mGluR5-dependent long-term depression. | Grueter BA et al. | β | 2008 | β |
| Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. | Blednov YA et al. | β | 2008 | β |
| MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. | Richardson HN et al. | β | 2008 | β |
| Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. | George DT et al. | β | 2008 | β |
| Review. Neurogenetic studies of alcohol addiction. | Crabbe JC | β | 2008 | β |
| Targets for ethanol action and antagonism in loop 2 of the extracellular domain of glycine receptors. | Perkins DI et al. | β | 2008 | β |
| Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. | Johnson BA | β | 2008 | β |
| Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. | Sommer WH et al. | β | 2008 | β |
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. | Soyka M et al. | β | 2008 | β |
| 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. | Gehlert DR et al. | β | 2007 | β |
| Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats. | Bowers MS et al. | β | 2007 | β |
| Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. | Mason BJ et al. | β | 2007 | β |
| A key role for corticotropin-releasing factor in alcohol dependence. | Heilig M et al. | β | 2007 | β |
| Alcoholism, craving, and hormones: the role of leptin, ghrelin, prolactin, and the pro-opiomelanocortin system in modulating ethanol intake. | Wurst FM et al. | β | 2007 | β |
| Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. | Caputo F et al. | β | 2007 | β |
| GABAergic modulation of binge-like ethanol intake in C57BL/6J mice. | Moore EM et al. | β | 2007 | β |
| Gender differences for ghrelin levels in alcohol-dependent patients and differences between alcoholics and healthy controls. | Wurst FM et al. | β | 2007 | β |
| Imagen: implications for addiction science and science policy. | Heilig M | β | 2007 | β |
| Pharmacotherapy of dual substance abuse and dependence. | Kenna GA et al. | β | 2007 | β |
| Preclinical and clinical pharmacology of alcohol dependence. | Tambour S et al. | β | 2007 | β |
| The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. | Colombo G et al. | β | 2007 | β |
| The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. | Marinelli PW et al. | β | 2007 | β |
| Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (gamma-hydroxybutyric aciduria). Hypotheses evolved from 25 years of patient evaluation, studies in Aldh5a1-/- mice and characterization of gamma-hydroxybutyric acid pharmacology. | Knerr I et al. | β | 2007 | β |
| Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. | Carai MA et al. | β | 2006 | β |
| Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism. | Ciccocioppo R et al. | β | 2006 | β |
| Phenotypic characterization of genetically selected Sardinian alcohol-preferring (sP) and -non-preferring (sNP) rats. | Colombo G et al. | β | 2006 | β |
| The genetic of alcoholism: learning from 50 years of research. | Ciccocioppo R et al. | β | 2006 | β |
| Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. | Hansson AC et al. | β | 2006 | β |